

IUS in pediatrics and pregnancy

Christos Tzivinikos

MD DCH FRCPCH MSc CEBP

Consultant Paediatric Gastroenterologist

Clinical Associate Professor at MBRU School of Medicine

Al Jalila Children's Specialty Hospital, Dubai ,UAE



Kuwait City, Kuwait, November 21st – 22nd, 2025

Disclosure

Intended Learning Outcome

By the end of this session, the learner will be able to:

Pediatrics

1. Explain the benefits and limitations of using intestinal ultrasound (IUS) in pediatric clinical practice.
2. Compare and contrast IUS inflammation cut-offs in pediatric versus adult populations.

Pregnancy

1. Discuss the anatomical challenges during pregnancy that impact the performance and interpretation of IUS.
2. Evaluate the effectiveness of IUS relative to standard care imaging modalities during pregnancy.

Intestinal USS in Paediatric IBD

- Same indications and utilization like in adult IBD
- Generally easier to perform due to smaller and less obese body habitus in pediatric IBD patients
- Linear probe usually sufficient and rectum is visible in younger kids
- Non invasive – reduction of re-assessment endoscopies under GA
- Very good acceptability and satisfaction by children and caregivers
- Patients with either Crohn disease or ulcerative colitis were both satisfied with TABUS, with it being particularly informative for those with severe IBD.
- Pediatric patients were not worried about potential TABUS findings, even in those with anxiety.

Intestinal USS in paediatric IBD

Advantages	Disadvantages
Can assess location of disease	Measurement of length of affected segment is less reliable than MRE
Can assess motility	Rectum not always visible
Can assess disease severity and complications	Learning curve
Can assess transmural healing	Operator dependency
Examination is noninvasive and radiation-free	Cutoff values and diagnostic accuracy are not yet established
Low costs	

- Completely satisfied/Strongly agree/Not at all worried
- Somewhat satisfied/Agree/A little worried
- Neutral/A little more worried
- Somewhat not satisfied/Disagree
- Strongly disagree


Pediatric Patient and Caregiver Satisfaction With the Use of Transabdominal Bowel Ultrasound in the Assessment of Inflammatory Bowel Diseases

Alexandra S. Hudson MD, FRCPC, Hien Q. Huynh MBBS, FRCPC, Kerri L. Novak MD, FRCPC, Henry Ma BSc, Anna Kuc BSc, Justin Kim BSc, Patricia Almeida MD ... See all authors

First published: 20 September 2022 | <https://doi.org/10.1097/MPG.0000000000003618> | Citations: 12

Pediatric patients

Caregivers



Percentage of participants

IUS – what to use for/replacing endoscopy or MRE

Diagnosis


- New Crohn's disease ☒ NO
- Flare of established diagnosis ☒ YES
- Complications ☒ YES
 - Fibrosis vs inflammation ☒ MAYBE
- Post-operative recurrence ☒ MAYBE ☒ YES

Monitoring

- Response in ileo-colonic ☒ YES
- Response in proximal SB ☒ MAYBE ☒ NO
- Treat to target ☒ MAYBE ☒ YES

Dysplasia surveillance

☒ NO






Intestinal Ultrasound for the Pediatric Gastroenterologist: A Guide for Inflammatory Bowel Disease Monitoring in Children

Expert Consensus on Behalf of the International Bowel Ultrasound Group (IBUS) Pediatric Committee

*Amelia Kellar, MD, MSc, *Michael Dolinger, MD, MBA, †Kerri L. Novak, MD, MSc, ‡Mallory Chavannes, MD, MHSc, *Marla Dubinsky, MD, and ‡Hien Huynh, MD



What Is Known

- Intestinal ultrasound (IUS) is an accurate, cross-sectional imaging tool used to monitor inflammation in inflammatory bowel disease.
- With comparable accuracy to computed tomography (CT) and magnetic resonance (MR), IUS is non-radiating, and applied at the bedside to facilitate real-time decision-making.

What Is New

- As IUS use is increasing, we provide a standardized approach and monitoring algorithm for use of pediatric bedside IUS to guide care.
- IUS is best performed at baseline to compliment endoscopy and during, or immediately after therapy induction. Monitoring every 3–6 months until treat-to-target colonoscopy is performed within 1 year is recommended.



ECCO Topical Review

ECCO-ESGAR Topical Review on Optimizing Reporting for Cross-Sectional Imaging in Inflammatory Bowel Disease

3.4.2. Transmural remission, definition, and timing of assessment in Crohn's disease

- 3.4.2.1. Transmural remission of the small and large bowel is defined by bowel wall thickness ≤ 3 mm with normal/0 colour Doppler signal. [InA. 0, Unc. 1, App. 17]
- 3.4.2.2. In some patients, sigmoid colon may contain an enlarged muscularis propria [outer hypoechoic layer typical in diverticular disease], allowing for bowel wall thickness up to 4 mm without resembling active inflammation. [InA. 3, Unc. 1, App. 13]

3.5.2. Transmural remission, definition, and timing of assessment in ulcerative colitis.

- 3.5.2.1. Transmural remission in ulcerative colitis of the large bowel is defined by bowel wall thickness ≤ 3 mm with normal/0 colour Doppler signal. [InA. 0, Unc. 1, App. 17]
- 3.5.2.2. In some patients, sigmoid colon may contain an enlarged muscularis propria [outer hypoechoic layer—typical in diverticular disease], allowing for bowel wall thickness up to 4 mm without resembling active inflammation. [InA. 3, Unc. 1, App. 13]

3.6. Adults vs. paediatric population

- | | |
|--------|--|
| 3.6.1. | The remission/response statements for Crohn's disease may be used in both adult and paediatric populations. [InA. 2, Unc. 1, App. 14] |
| 3.6.2. | The remission/response statements for ulcerative colitis may be used in both adult and paediatric populations. [InA. 2, Unc. 2, App. 12] |

There was only one paediatrician involved in our RAND/UCLA process. However, based on the limited available evidence from paediatric studies presented throughout this article [[Supplementary Table 3](#)],^{56,59,61,88,92,93} we find that our recommendations may be used in both populations. Future studies are needed to validate or refute this assumption.



Assessing Disease Activity in Pediatric Crohn's Disease Using Ultrasound


The Pediatric Crohn Disease Intestinal Ultrasound Score

Elsa A. van Wassenauer MD, PhD ✉, Rick R. van Rijn MD, PhD, Floris A.E. de Voogd MD, PhD, Joost van Schuppen MD, Angelika Kindermann MD, PhD, Tim G.J. de Meij MD, PhD ... See all authors

First published: 07 February 2023 | <https://doi.org/10.1097/MPG.0000000000003727> | Citations: 14

TI		Colon:	
BWT 2.0–3.0 mm:	1 point	BWT 1.6–2.0:	1 points
BWT 3.0–3.7 mm:	2 points	BWT 2.0–2.7 mm:	2 points
BWT >3.7 mm:	3 points	BWT >2.7 mm:	3 points
		Mesenteric fat infiltration:	1 point

PCD-US score of ≥ 3 points, that is, colonic BWT > 2.0 mm combined with fat infiltration, or a BWT > 3.7 or >2.7 mm for TI and colon respectively, had a high probability of endoscopic disease activity (specificity 88% and 92%, positive LR: 4.37 and 5.50 for TI and colon, respectively).



7 included studies

Reported ULN 1.9mm

<5 years even thinner BWT




Fig. 2 Mean bowel wall thickness (BWT) in millimeters (mm) per age category, displayed per segment. Differences were tested with analysis of variance and subsequently with Student's *t*-tests for independent samples.

P-values were corrected for multiple testing with the Bonferroni method.
Miscellaneous: age range 3–18 years

Do children with IBD in sustained deep remission have the same bowel wall thickness as adults?


Background

- Remission values for bowel wall thickness (BWT) on intestinal ultrasound (IUS) for children with IBD are extrapolated from adults
- We evaluated BWT on IUS in children with IBD in sustained deep remission



Cohort and Design

- Cross-sectional study of children with IBD



Outcome of Interest



- Segmental BWT
- Effect of patient and disease characteristics

Results

- Normal BWT in children with IBD in deep remission is less than adults
- BWT is unaffected by age, sex, and bowel segment



Baseline Patient Demographics

Subjects	N (%), or median [IQR]
Female	40 (40.8)
Age (years)	15.2 [13.8-16.8]
Height (cm)	164.8 [157.0-172.7]
Weight (Kg)	56.6 [46.4-66.4]
Disease duration at time of IUS (years)	2.6 [1.2-4.3]
CD:UC:IBD-U	64 (65.3): 29 (29.6): 5(5.1)
CD Lower gastrointestinal involvement (n=64)	
L1: Ileal	29 (47)
L2: Colonic	8 (14)
L3: Ileocolonic	27 (39)
UC/IBD-U Disease Location (n=34)	
E1: Ulcerative Proctitis	0 (0)
E2: Left-sided Colitis	6 (17.6)
E3: Extensive Colitis	7 (20.6)
E4: Pancolitis	21 (61.8)

Defining normal bowel wall thickness in children with inflammatory bowel disease in deep remission: A multicenter study on behalf of the pediatric committee of the International Bowel Ultrasound Group (IBUS)

Amelia Kellar ✉, Mallory Chavannes, Hien Q. Huynh, Illya Aronskyy, Bryan Lei, Jennifer C. deBruyn, Justin Kim, Michael T. Dolinger

First published: 29 April 2025 | <https://doi.org/10.1002/jpn3.70049> | Citations: 4


What is Known

- Intestinal ultrasound (IUS) is a noninvasive, patient-centric tool for monitoring disease activity in children with inflammatory bowel disease (IBD).
- Bowel wall thickness (BWT) is the most important parameter for assessing IBD activity.

What is New

- Previously inflamed BWT for children with IBD in sustained deep remission is less than 3 mm seen in adults, and unaffected by age, sex, and bowel segment in this population.
- BWT may be affected by weight and disease duration.
- These findings are crucial to the standardized assessment of transmural healing in children.

Segmental bowel wall thickness



Univariate associations between bowel wall thickness (BWT) and clinical parameters, unadjusted and adjusted for colonic segments as a fixed effect.

Parameter	Unadjusted beta co efficient [95% CI]	P-value	Adjusted beta co-efficient [95% CI]	P -value
Age (years)	0.023 (0.001 – 0.045)	0.039	0.023 (0.001 – 0.045)	0.039
Sex (male reference)	-0.005 (-0.120 – 0.110)	0.929	-0.005 (-0.120 – 0.110)	0.936
Height (cm)	0.003 (-0.001 – 0.007)	0.127	0.003 (-0.001 – 0.007)	0.130
Weight (kg)	0.004 (0.001 – 0.008)	0.014	0.004 (0.001 – 0.007)	0.016
Disease Duration (months)	-0.024 (-0.047 – -0.001)	0.046	-0.024 (-0.047 – 0.001)	0.046
Diagnosis of UC (CD reference)	-0.120 (-0.243 – 0.002)	0.059	-0.120 (-0.243 – 0.002)	0.059
Diagnosis of IBDU	-0.133 (-0.387 – 0.121)	0.309	-0.133 (-0.387 – 0.121)	0.310

Comparison between segmental of wall thickness in previously inflamed segments and uninvolved bowel segments

Bowel Segments (n=322)	Previously inflamed Segments Median BWT (IQR)	Uninvolved Segments Median BWT (IQR)	P-value
All segments (mm)	1.35 (1.10-1.60)	1.30 (1.01-1.60)	0.625
Terminal Ileum (mm)	1.45 (1.28-1.85)	1.13 (1.00-1.42)	0.003
Ascending Colon (mm)	1.35 (1.1-1.50)	1.30 (1.10-1.50)	0.682
Transverse Colon (mm)	1.21 (1.00-1.68)	1.35 (1.03-1.60)	0.810
Descending Colon (mm)	1.31 (1.11-1.56)	1.60 (1.10-1.90)	0.053
Sigmoid Colon (mm)	1.30 (1.03-1.49)	1.40 (1.10-1.77)	0.605

- Median BWT was 1.4mm [1.1-1.6] with no differences in bowel segments
- BWT is affected weight and duration of disease
- Previously inflamed BWT for children with IBD in sustained deep remission is less than 3mm in adults
- It is not designed to determine the best cut-off for predicting abnormality.


In multivariate analysis (mixed-effect model)

- A significant positive association remained between BWT and weight [adjusted $\beta=0.006$ (95% CI 0.001-0.011), $p=0.038$]
- A significant negative association between BWT and disease duration [adjusted $\beta=-0.028$ (95% CI -0.052- -0.003), $p=0.038$].


Four intestinal ultrasound scores and bowel wall thickness alone correlated well with pediatric ulcerative colitis disease activity

Alexandra S. Hudson, Daniela M. Isaac, Henry Ma, Christine Lo, Justin Kim, Anna Kuc, Kerri L. Novak, Matthew W. Carroll, Eytan Wine, Hien Q. Huynh

- Prospective enrolment
- 52 pediatric new UC (206 colon segments)
- IUS (BWT and 4 scores) correlated:
 - Best with endoscopy
 - Then with symptoms (PUCAI), CRP, albumin
 - Weakest with ESR and Fcal
- Patients needing hospital admission had worse IUS



Pediatric UC




UC-IUS score:

BWT: >2mm=1, >3mm=2, >4mm=3

Doppler signal: spots=1, stretches=2


Haustrations: abnormal=1

Fat wrapping: present=1



Pediatric UC Over Time

- Prospective enrolment
- **42 patients (168 colon segments)**
- IUS (BWT and UC-IUS score) **correlated over 1 year:**
 - PUCAI
 - Biochemical markers
 - Endoscopy
- Biggest decrease in BWT **during the first month** (average 40% decrease)




Bedside Intestinal Ultrasound Predicts Disease Severity and the Disease Distribution of Pediatric Patients With Inflammatory Bowel Disease: A Pilot Cross-sectional Study


Mallory Chavannes, MD, MHSc,^{*,†} Lara Hart, MD, MSc,[†] Panteha Hayati Rezvan, PhD,[‡] Jonathan R. Dillman, MD, MS, MSc,[§] and D. Brent Polk, MD[¶]

Inflam Bowl Diseases 2024

A Bowel wall thickness by endoscopic severity graded by SES-CD



B Bowel wall thickness by endoscopic severity graded by UCEIS



Pediatric Crohn's The TI

Simplification Model into PCD-US Score

Based on the results of the multivariate regression analyses, a point-based index was made. The points assigned to each variable (ie, the calculation of the PCD-US score) are as follows:

TABLE 3A. Testing characteristics of PCD-US score for endoscopic disease activity in TI


TI		Sensitivity (95% CI)		Specificity (95% CI)
		<i>No inflammation versus inflammation</i>		
BWT 2.0–3.0 mm:	1 point	≥1 point	82 (65–93)%	42 (25–61%)
BWT 3.0–3.7 mm:	2 points	≥2 points	65 (47–80)%	73 (54–87)%
BWT >3.7 mm:	3 points	3 points	53 (35–70)%	88 (72–97)%

74 patients


Wassenaar et al 2023 JPGN


Pediatric Crohn's over time

BWT of the most severe segment
N=61 patients



SUS-CD Score of most severe segment
BWT 1 (≥3mm), 2 (≥5mm), 3 (≥8mm)
Hyperemia 1 (2-5 vessels/cm²), 2 (>5 vessels/cm²)





AUTOMATIC PEDIATRIC IBD ASSESSMENT IN INTESTINAL ULTRASOUND IMAGES USING MACHINE LEARNING

Logiraj Kumaralingam¹, Kenneth Le May², Van Bao Dang¹, Javaneh Alavi¹, **Hien Q. Huynh**², Lawrence H. Le¹


¹Department of Radiology and Diagnostic Imaging, University of Alberta, Edmonton, Alberta, Canada

²Department of Pediatrics, University of Alberta, Edmonton, Alberta, Canada.

IUS Abnormal vs. Normal Images

- **Gold-standard Measurements:**

- ❖ Experienced clinician trained in IUS
- ❖ Terminal ileum, cecum, ascending, transverse, descending, and sigmoid colons
- ❖ At least two measurements from both proximal and distal sections except for cecum.
- ❖ Classification were validated by:
 - Colonoscopy
 - Magnetic Resonance Enterography (MRE)



Dataset Details

- **Patient Demographics:**

- Total: 260 pediatric patients
- Age Range: 11 months to 18 years (Median: 13; Mean: 12.89)
- Gender: 109 females, 151 males


- **Image Dataset:**

- Total Longitudinal Images: 4,565
- Abnormal: 1,478 images from 177 patients (94 CD and 83 UC)
- Normal: 3,087 images from 83 normal patients and normal segments of those with IBD


- **Enrollment and Scanning:**

- Enrollment Period: April 2020 – May 2023
- Single centre: Edmonton Pediatric IBD Clinic & Stollery Children's Hospital, Alberta, Canada
- Scanner: Philips EPIQ 5q ultrasound with linear L12-5 probe

Pediatric Patients



Collected Dataset



Total # of IUS Images = 4565

IUS image Acquisition

- Ultrasound Philips Epiq5 machine using linear L12-5 probe.





Statistical BWT Analysis (Testing Images=3953)

Classes	Median (25 th – 75 th interquartile range)	
	Manual Measurements (mm)	Automatic Measurements (mm)
Abnormal	3.05 (2.49 – 4.01)	3.18 (2.54 – 4.12)
Normal	1.30 (1.12 – 1.52)	1.19 (0.97 – 1.48)

ICC: 0.942 (95% CI: 0.938-0.946)

R² value: 0.89 (indicating high agreement)

Sensitivity Analysis of Average BWT Across Various Cut-Offs



- **2 mm** was an optimal cut-off for distinguishing abnormal and normal cases with highest (>90%) sensitivity and specificity.

Conclusions

- AI automates BWT measurements, which correlate highly with manual measurements by trained clinicians
- **In children with IBD, a lower cut-off of 2 mm BWT gives a better sensitivity without losing too much specificity in detecting transmural inflammation**
- This can provide clinicians with an **advanced tool** for accurate assessment of BWT, reducing workload, and boosting efficiency

Definition of IUS Response to Predict Endoscopic Remission is Poorly Understood

- Changes in bowel wall thickness (BWT) can be seen in response to biologic treatment of adults with CD¹
- BWT in the terminal ileum (TI) of children with CD treated with anti-TNF therapy has been shown to decrease over time²
- Expert consensus definition of IUS response at 14 + 2 weeks after treatment initiation³:
 - > 25% reduction in BWT
 - > 2 mm decrease in BWT
 - May be beneficial to assess IUS response between 4-8 weeks in certain situations
- Study of 31 adults with TI and colonic CD treated with anti-TNF therapy found an 18% reduction in BWT 4-8 weeks after treatment initiation predicted endoscopic response at weeks 12-34⁴

Early Intestinal Ultrasound Response to Biologic Therapy Predicts Endoscopic Remission in Children with Ileal Crohn's Disease: Results from the Prospective Super Sonic Study



Michael Todd Dolinger¹, Illya Aronskyy¹, Amelia Kellar¹, Elizabeth Spencer¹,
Nanci Pittman¹, Marla C Dubinsky¹

Background and Aims: STRIDE-II recommends early biomarker targets for treatment optimization to achieve treat-to-target (T2T) endoscopic remission [ER] in Crohn's disease [CD]. The predictive capabilities of intestinal ultrasound [IUS] for T2T ER remain unknown. We aimed to evaluate IUS response to predict ER in children with CD.

Methods: This was a prospective longitudinal cohort study of children with ileal [TI] CD initiating biologic therapy undergoing IUS, clinical disease activity, and C-reactive protein [CRP] assessments at baseline, week 8, 6 months, and T2T within 1 year. The primary outcome was the accuracy of optimal cut-points to predict TI ER [SES-CD ≤ 2] for change in bowel wall thickness [BWT] on IUS from baseline to week 8, and BWT at week 8. Area under the receiver operating curve [AUROC] analysis was performed and univariate analysis tested associations.

Results: In total, 44 children (median age 13 [IQR 12–17] years, 29 [66%] biologic naïve) were included, and 29 [66%] achieved ER. A $\geq 18\%$ decrease in TI BWT at week 8 predicted ER with an AUROC of 0.99 [95% CI 0.98–1.00], 100% sensitivity, 93% specificity, 97% positive predictive value, and 100% negative predictive value, superior to a $\geq 46\%$ decrease in PDAI (AUROC 0.67 [95% CI 0.49–0.84]) and $\geq 84\%$ decrease in CRP (AUROC 0.49 [95% CI 0.31–0.67]) at week 8.

Conclusions: Early change in TI BWT on IUS is highly predictive of ER in children with CD and superior to symptoms and CRP. Our findings suggest that IUS could be used for treatment optimization and tight control to guide T2T strategies.




Evaluation of Early IUS Response in Children with CD


- Aimed to evaluate if early IUS response at week 8 predicts T2T endoscopic outcomes in children with T1 CD initiating biologic therapy
- To compare if early changes on IUS are superior to early changes in clinical disease activity and CRP to predict T2T endoscopic outcomes



A Terminal Ileum Bowel Wall Thickness Over Time Stratified by T2T Endoscopic Remission




B Percentage Decrease in Terminal Ileum Bowel Wall Thickness from Baseline




Percentage Change in Bowel Wall Thickness from Baseline To Predict Endoscopic Remission


18.2% BWT Decrease



33.3% BWT Decrease



46.5% BWT Decrease



1 - Specificity

1 - Specificity

1 - Specificity





Week 8

6 months

Treat-To-Target

Normalization of IUS parameters in children who achieve endoscopic remission vs children who do not achieve



Reliability and Validity of Mesenteric Fat Assessment by Intestinal Ultrasound in Pediatric Crohn's Disease Using the Chicago Mesenteric Fat Index

[Get access >](#)

Amelia Kellar, MD, MSc, Tessa George, BS, Michael T Dolinger, MD, MBA,
[Matthew Smyth, MD](#), Noa Krugliak Cleveland, MD, David T Rubin, MD,
Joëlle St-Pierre, MD, PhD ✉

Inflammatory Bowel Diseases, izaf238, <https://doi.org/10.1093/ibd/izaf238>

Published: 06 November 2025 **Article history** ▼

Methods

Children (≤ 18 years of age) with ileal CD who underwent IUS at 2 centers were enrolled. Three expert sonographers independently graded MF as present/absent and by the CMFI. IRR was calculated using Fleiss' kappa coefficient. Correlations between MF and clinical characteristics, inflammatory markers, and IUS data were calculated.

Results

Eighty IUS exams in 67 patients were included. The IRR was substantial for binary MF ($\kappa = 0.744$) and CMFI ($\kappa = 0.618$). Increasing CMFI grade was associated with bowel wall thickness ($P < .001$; odds ratio [OR], 16.35; 95% confidence interval [CI], 5.74–46.58), presence of ileal stricture ($P < .001$; OR, 30.32; 95% CI, 5.74–160.15), and presence of hyperemia ($P = .001$; OR, 6.59; 95% CI, 2.27–19.09).

Conclusion

Assessment of MF on IUS is reproducible and reliable in pediatric CD. The CMFI can be used as a biomarker that mirrors biochemical and sonographic indicators of pediatric CD activity.



Take home points

- In pediatric IBD, the BWT cut-off for response and remission is not $\leq 3\text{mm}$
- $\leq 2\text{mm}$ is likely the ideal cut-off in both pediatric UC and CD
 - The terminal ileum may have a slightly higher BWT cut-off compared to the colon
- Inflammatory bowel segments in remission resemble normal bowel
 - Further research is needed for fibrostenotic bowel segments (treated stricturing and/or penetrating disease), likely to remain thicker

Value of transabdominal ultrasonography for diagnosing functional constipation in children: a systematic review and meta-analysis

Duc Long Tran, MD^{1,2}, Phu Nguyen Trong Tran, MD^{1,2}, Paweena Susantitaphong, MD, PhD^{3,4}, Phichayut Phinyo, MD⁵, Palittiya Sintusek, MD, PhD⁶

Transverse lower abdominal ultrasonography (broken line) of (a) Rectal diameter and (b) Anterior rectal wall



Expert position statement: Defining the role of intestinal ultrasound in assessing constipation and faecal loading

International Expert Panel

- 15 panel members
 - 13 adult gastroenterologists
 - 1 paediatric gastroenterologist
 - 1 radiologist
 - 2 DGBI experts

RAND/UCLA voting methodology

57 statements generated from a systematic review

2 rounds of voting

O
N
L
I
N
E

V
O
T
I
N
G

Results


43 statements appropriate
3 statements inappropriate
5 statements uncertain

IUS considered appropriate in the assessment of functional gut disorders

Posterior acoustic shadowing and colonic distension are important sonographic features of faecal loading

Lack of prospective adult studies

Sonographic Faecal Loading



An expert panel of gastroenterologists concluded that intestinal ultrasound is an appropriate modality to investigate constipation and faecal loading in patients and further well-designed studies are warranted to further define sonographic parameters of faecal loading and broaden its application to functional gastrointestinal disorders

Mathias, et al. *Aliment. Pharmacol. Ther.* Oct 2025

AP&T

A rectal diameter >30 mm to define faecal loading in paediatric patients

Intended Learning Outcome

By the end of this session, the learner will be able to:

Pediatrics

1. Explain the benefits and limitations of using intestinal ultrasound (IUS) in pediatric clinical practice.
2. Compare and contrast IUS inflammation cut-offs in pediatric versus adult populations.


Pregnancy

1. Discuss the anatomical challenges during pregnancy that impact the performance and interpretation of IUS.
2. Evaluate the effectiveness of IUS relative to standard care imaging modalities during pregnancy.



Monitoring of Inflammatory Bowel Disease in Pregnancy: A Review of the Different Modalities

Reem Al-jabri ¹, Panu Wetwittayakhleng ² and Peter L. Lakatos ^{1,3,*}





Disease Management during Pregnancy

IBD is associated with higher risk of adverse pregnancy outcomes compared to non-IBD pregnancies

- **Prematurity:** 1.87-fold increase (<37wk gestation; 95% CI 1.52 to 2.31; $p<0.001$)
- **Low birth weight:** 2-fold increase (<2500 g; 95% CI 1.38 to 3.19; $p<0.001$).
- **Congenital abnormalities:** 2.37-fold increase (95% CI 1.47 to 3.82; $p<0.001$)
- **Cesarean delivery:** 1.5-fold (95% CI 1.26 to 1.79; $p<0.001$)

	Flaring UC	Flaring CD
Premature birth	OR 2.72	OR 2.66
Low birth weight	OR 2.10	OR 3.3
Stillbirth/miscarriage/abortion	4-fold increase	5-fold increase



Monitoring IBD during Pregnancy

IBD in remission

- GI visit in 1st trimester and then as needed (each trimester)
- Labs at every trimester, consider FCP, TDM in 2nd trimester
- Examine perineum for evidence of active disease

IBD flare

Diagnostics

- **Ultrasound**
- **Endoscopy:** perform when result will change management, prefer flexible sigmoidoscopy unprepped, unsedated in any trimester
- **MR:** gadolinium should be avoided
- **CT:** a single CT scan (50mGy) is below the level of concern

From: **Intestinal Ultrasonography Diagnostic Performance and Feasibility in IBD during Pregnancy: A Systematic Review and Narrative Synthesis**

Inflamm Intest Dis. 2024;9(1):229-240. doi:10.1159/000541017




ECCO-ESGAR-ESP-IBUS Guideline on Diagnostics and Monitoring of Patients with Inflammatory Bowel Disease:

- Beyond 20 weeks,:
- colonic views were adequate in almost all cases
 - but the ileocaecal valve and terminal ileum became more difficult to visualize, with an adequate window in approximately 50% of cases

	Risk of Bias				Applicability Concerns		
	Patient Selection	Index Test	Reference Standard	Flow and Timing	Patient Selection	Index Test	Reference Standard
De Voogd et al., 2021	+	+	?	+	+	+	?
Flanagan et al., 2020	?	+	?	+	+	+	?
Leung et al., 2017	+	+	?	+	+	+	?
<div><div>High</div><div>Unclear</div><div>Low</div></div>							

IUS in IBD during Pregnancy: Feasibility

Figure 1: Visualization of bowel segments in pregnant IBD patients per trimester



Original Article

**Monitoring Inflammatory Bowel Disease
in Pregnancy Using Gastrointestinal
Ultrasonography**Emma Flanagan,^{a,✉} Emily K. Wright,^b Jakob Begun,^{c,✉} Robert V. Bryant,^d
Yoon-Kyo An,^c Alyson L. Ross,^e Katerina V. Kiburg,^a Sally J. Bell^a**Results:**

Ninety patients and 127 GIUS examinations were included [median gestation 19 weeks, range 4–33]. Adequate colonic views were obtained in 116/127 [91%] scans.

Adequate ileal views were obtained in 62/67 [93%] scans <20 weeks and 30/51 [59%] scans at 20–26 weeks. positive correlation between bowel wall thickness and calprotectin [$r = 0.26$, $p = 0.03$].

GIUS delivered aspecificity of 83%, sensitivity of 74%, and negative predictive value of 90% compared with calprotectin

Conclusions:

GIUS is a feasible and accurate modality for monitoring IBD in pregnancy.

Adequate GIUS views of the colon and terminal ileum can be obtained in the majority of patients up to 20 week gestation


Beyond 20 weeks, GIUS provides good views of the colon but the terminal ileum becomes difficult to assess.

Feasibility of IUS in pregnancy

Patients

38 patients with IBD, 27 patients having serial IUS during their pregnancy

Intervention: IUS in each trimester compared with clinical disease activity and FCal as reference standard



	Trimester 1 (n = 22)	Trimester 2 (n = 23)	Trimester 3 (n = 20)
Sensitivity	83.3%	92.3%	66.6%
Specificity	93.8%	100%	100%
AUROC (95% CI)	0.891 (0.702–1.000), $P = .006$	0.923 (0.802–1.000), $P < .0001$	0.813 (0.591–1.000), $P = .021$


Active disease defined as fecal calprotectin ≥ 250 $\mu\text{g/g}$ or fecal calprotectin ≥ 100 $\mu\text{g/g}$ and HBI ≥ 4 /SCCAI ≥ 3 .

Results


- Feasibility decreases in the third trimester in the TI and sigmoid
- IUS detected active disease with 98% specificity throughout pregnancy




Active Inflammatory Bowel Disease on Intestinal Ultrasound During Pregnancy Is Associated With an Increased Risk of Adverse Pregnancy and Neonatal Outcomes Independent of Clinical and Biochemical Disease Activity



Risk of adverse obstetric outcomes according to active IUS in T1 and/or T2



Active Inflammatory Bowel Disease on Intestinal Ultrasound During Pregnancy Is Associated With an Increased Risk of Adverse Pregnancy and Neonatal Outcomes Independent of Clinical and Biochemical Disease Activity



Agreement between assessment activity tools

FCP HBI/SCCAI

minimal in T1 (0.29) & T2 (0.29), **none** in T3 (0.07)

IUS

minimal in T1 (0.35) & **none** in T2 (0.08)

Gastroenterology